1.77
-0.025(-1.39%)
Currency In USD
| Previous Close | 1.8 |
| Open | 1.78 |
| Day High | 1.83 |
| Day Low | 1.77 |
| 52-Week High | 3.19 |
| 52-Week Low | 0.89 |
| Volume | 121,887 |
| Average Volume | 268,939 |
| Market Cap | 53M |
| PE | -2.16 |
| EPS | -0.82 |
| Moving Average 50 Days | 1.9 |
| Moving Average 200 Days | 1.93 |
| Change | -0.03 |
If you invested $1000 in Gain Therapeutics, Inc. (GANX) since IPO date, it would be worth $145.08 as of June 01, 2025 at a share price of $1.77. Whereas If you bought $1000 worth of Gain Therapeutics, Inc. (GANX) shares 3 years ago, it would be worth $621.05 as of June 01, 2025 at a share price of $1.77.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
GlobeNewswire Inc.
May 29, 2025 12:45 PM GMT
BETHESDA, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ther
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
GlobeNewswire Inc.
May 12, 2025 11:30 AM GMT
GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activityBETHESDA, Md., May 12, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (N
Gain Therapeutics to Participate at The Citizens Life Sciences Conference
GlobeNewswire Inc.
May 01, 2025 11:30 AM GMT
BETHESDA, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ther